Which statement about RSV prevention with Synagis is accurate?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Prepare for the Pediatric Respiratory Exam with our comprehensive study materials. Engage with flashcards and multiple-choice questions. Each question comes with hints and explanations. Get exam-ready with confidence!

Multiple Choice

Which statement about RSV prevention with Synagis is accurate?

Explanation:
Palivizumab (Synagis) is a form of passive immunoprophylaxis used to prevent RSV disease in high‑risk infants during the RSV season. It provides antibodies to reduce the risk of RSV hospitalization and is given before or during exposure in order to prevent illness. It is not a treatment for an established RSV infection and it does not cure RSV. Because of that, its role is strictly primary prevention, not therapeutic after infection.

Palivizumab (Synagis) is a form of passive immunoprophylaxis used to prevent RSV disease in high‑risk infants during the RSV season. It provides antibodies to reduce the risk of RSV hospitalization and is given before or during exposure in order to prevent illness. It is not a treatment for an established RSV infection and it does not cure RSV. Because of that, its role is strictly primary prevention, not therapeutic after infection.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy